Interleukin 8, Recombinant, Human, 72aa (IL-8)

Lyophilized powder may be stored at 4 °C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 °C. Reconstituted product is stable for 12 months at -20 °C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

[interleukin-8; Interleukin-8; interleukin-8; emoctakin; OTTHUMP00000199824; OTTHUMP00000199825; C-X-C motif chemokine 8; T cell chemotactic factor; T-cell chemotactic factor; neutrophil-activating peptide 1; chemokine (C-X-C motif) ligand 8; beta-thromboglobulin-like protein; granulocyte chemotactic protein 1; tumor necrosis factor-induced gene 1; alveolar macrophage chemotactic factor I; monocyte-derived neutrophil chemotactic factor; monocyte-derived neutrophil-activating peptide; small inducible cytokine subfamily B, member 8; lymphocyte-derived neutrophil-activating factor; lymphocyte derived neutrophil activating peptide; lung giant cell carcinoma-derived chemotactic protein; beta endothelial cell-derived neutrophil activating peptide; interleukin 8; C-X-C motif chemokine 8; Emoctakin; Granulocyte chemotactic protein 1; GCP-1; Monocyte-derived neutrophil chemotactic factor; MDNCF; Monocyte-derived neutrophil-activating peptide; MONAP; Neutrophil-activating protein 1; NAP-1; Protein 3-10C; T-cell chemotactic factorCleaved into the following 7 chains:MDNCF-a; Alternative name(s):; GCP/IL-8 protein IV; IL8/NAP1 form IInterleukin-8; Alternative name(s):; (Ala-IL-8)77; GCP/IL-8 protein II; IL-8(1-77); IL8/NAP1 form II; MDNCF-bIL-8(5-77)IL-8(6-77); Alternative name(s):; (Ser-IL-8)72; GCP/IL-8 protein I; IL8/NAP1 form III; Lymphocyte-derived neutrophil-activating factor; LYNAP; MDNCF-c; Neutrophil-activating factor; NAFIL-8(7-77); Alternative name(s):; GCP/IL-8 protein V; IL8/NAP1 form IVIL-8(8-77); Alternative name(s):; GCP/IL-8 protein VI; IL8/NAP1 form VIL-8(9-77); Alternative name(s):; GCP/IL-8 protein III; IL8/NAP1 form VI]